Table 4 Clinical, functional, and laboratory data presented as the difference between results at baseline and at 6 months according to prior biologic therapy use
From: Real-life experience with benralizumab during 6 months
Variables | Biologic treatment-naïve patients (n = 20) | Patients with prior biologic therapy (n = 22) | p |
|---|---|---|---|
Subjective improvement*, n (%) | 20 (100) | 18 (81.8) | 0.487 |
Corticosteroid-dependent at 6 months, n (%) | 4 (20) | 4 (18.2) | 0.125 |
ACT*, md (IR) | 8 (5) | 5.5 (4) | 0.196 |
No. of ED visits at 6 months; md (IR) | 1 (5) | 2 (10) | 1 |
Post-BD FEV1, mL*; md (IR) | 330 (350) | 238 (375) | 0.279 |
Post-BD FEV1, %*; md (IR) | 11 (8) | 7.5 (15) | 0.424 |
FeNO, ppb*; md (IR) | 40 (28) | 34 (45) | 0.316 |
Blood eosinophil count, cells/ÎĽL*; md (IR) | 755 (312) | 692 (221) | 0.274 |